Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 2491 • 2015 ACR/ARHP Annual Meeting
Documentation of Disease Activity Score As Part of a Treat to Target Strategy in Rheumatoid Arthritis
Sarah Homann¹ and Beth Scholz², ¹Rheumatology, University of Texas Health Sciences Center at Houston, Houston, TX, ²University of Texas Health Sciences Center at Houston, Houston, TX
Background/Purpose: Compared to routine care, the Treat to Target (TTT) strategy for rheumatoid arthritis (RA) has been validated to improve functional and radiographic outcomes via…
Abstract Number: 458 • 2015 ACR/ARHP Annual Meeting
First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Boulos Haraoui¹, Louis Coupal², Radmila Day³, Lionel Budry⁴ and Youb Chalabi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ³None, Montreal, QC, Canada, ⁴Bristol Myers Squibb Canada, St-Laurent, QC, Canada, ⁵Bristol Myers Squibb, Montreal, QC, Canada
Background/Purpose: The subcutaneous (SC) formulation of abatacept (ABA) has been available in Canada since January 2014. Here we report first year experience with SC ABA…
Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Rieke Alten¹, Robert J. Holt², Jeffrey D. Kent³ and Frank Buttgereit⁴, ¹Charité Univ Medicine, Berlin, Germany, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ⁴Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…
Abstract Number: 490 • 2015 ACR/ARHP Annual Meeting
Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Eric M. Ruderman¹, Jennifer Beaumont², Azra Muftic², Arthur M. Mandelin II¹, Amy Eisenstein², George J. Greene² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The treat to target (T2T) approach has become part of the standard of care in RA management. Implicit in this approach is patient involvement…
Abstract Number: 2735 • 2015 ACR/ARHP Annual Meeting
Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li², E Alemao³, S Deveikis¹ and J Kremer⁵, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: It has been postulated that patients with longstanding RA have more treatment-resistant disease. We propose to examine whether disease duration is an independent predictor…
Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Xin Wang¹, Arthur Kavanaugh², Désirée van der Heijde³, Maxime Dougados⁴, Stefan Florentinus¹, Yihan Li¹, Iain Sainsbury¹ and Josef S. Smolen⁵, ¹AbbVie Inc., North Chicago, IL, ²University of California San Diego, La Jolla, CA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴René Descartes University and Hôpital Cochin, Paris, France, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…
Abstract Number: 2743 • 2015 ACR/ARHP Annual Meeting
Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis
Paul Emery¹, Roy Fleischmann², Stephen Xu³ and Elizabeth C. Hsia^3,4, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ³Janssen Research & Development, LLC, Spring House, PA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Management guidelines recommend patients (pts) with RA should be treated with the intent of reaching a clinical target of low disease activity or remission…
Abstract Number: 560 • 2015 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li⁵, E Alemao³, S Deveikis⁴ and J Greenberg^1,6, ¹Corrona, LLC, Southborough, MA, ²Dept of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Response to therapies may vary based on anti-citrullinated protein antibodies (ACPA) status. We compared treatment response to abatacept in ACPA-positive versus -negative RA patients…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 574 • 2015 ACR/ARHP Annual Meeting
Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis
Shannon Sweeney¹, Arthur Kavanaugh², Alessia Lodi³, Bo Wang¹, David L. Boyle⁴, Stefano Tiziani⁵ and Monica Guma⁶, ¹University of Texas at Austin, Austin, TX, ²University of California San Diego, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁵Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁶Pharmacology, University of California, San Diego, La Jolla, CA
Background/Purpose: We hypothesized that characterization of patients’ metabolic profiles, utilizing both high-resolution 1H-nuclear magnetic resonance (NMR) and mass spectrometry (MS), might help predict response to…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 972 • 2015 ACR/ARHP Annual Meeting
A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)
Ronald F. van Vollenhoven¹, Edward C. Keystone², Vibeke Strand³, Cesar Pacheco-Tena⁴, Jiri Vencovsky⁵, Frank Behrens⁶, Daniela Zipp⁷, Faiza Rharbaoui⁸, Ralf Wolter⁹, Rolf-Dietrich Tiemann¹⁰, Luise Knierim¹¹, Rainer Schmeidl¹¹, Xuefei Zhou¹², Silke Aigner^8,13, Benjamin Daelken¹⁴ and Andrea Wartenberg-Demand^8,12, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Landseinerstr 5, Biotest AG, Dreieich, Germany, ⁸Biotest AG, Dreieich, Germany, ⁹Corporate Clinical Research, L, Biotest AG, Dreieich, Germany, ¹⁰Data Management and Outsourcing, Biotest AG, Dreieich, Germany, ¹¹Cooperate Drug Safety, Biotest AG, Dreieich, Germany, ¹²Cooperate Clinical Research, Biotest AG, Dreieich, Germany, ¹³Landsteinerstrasse 5, Biotest AG, Dreieich, Germany, ¹⁴Project Managerment Office, Biotest Pharmaceuticals Corporation, Boca Raton, FL
Background/Purpose: In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb,…
Abstract Number: 3111 • 2015 ACR/ARHP Annual Meeting
Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Gerd Burmester¹, IB McInnes², JM Kremer³, P Miranda⁴, J Vencovský⁵, A Godwood⁶, M Albulescu⁶, D Close⁶ and Michael Weinblatt⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³The Albany Medical College, Albany, NY, ⁴Centro De Estudios Reumatológicos, Santiago, Chile, ⁵Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic, ⁶MedImmune, Cambridge, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Modulating macrophage function through GM–CSF is a novel therapeutic approach for RA. Mavrilimumab, a fully human monoclonal antibody, which targets GM–CSFR-α, has demonstrated efficacy…
Abstract Number: 1002 • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Early RA: Impact on Pain during the First Year of Treatment
Ellen Moholt¹, Anna-Birgitte Aga¹, Inge C Olsen¹, Hilde Berner Hammer², Till Uhlig³, Anne Katrine Kongtorp⁴, Heidi Lunoe⁴, Elin Mejdell Styrmoe⁴, Tore K. Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC study group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Pain is the symptom people with rheumatoid arthritis (RA) have prioritized highest for improvement [1]. Treating to target and aiming for remission in early…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].